Sorrento Therapeutics Inc (SRNE)
0.016
0.00 (0.00%)
USD |
OTCM |
May 06, 15:56
Sorrento Therapeutics Cash from Financing (Quarterly): 88.81M for June 30, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2023 | 88.81M |
| March 31, 2023 | 61.20M |
| December 31, 2022 | 25.08M |
| September 30, 2022 | 71.50M |
| June 30, 2022 | 41.77M |
| March 31, 2022 | 173.37M |
| December 31, 2021 | 70.86M |
| September 30, 2021 | 40.06M |
| June 30, 2021 | 35.06M |
| March 31, 2021 | 35.36M |
| December 31, 2020 | -11.58M |
| September 30, 2020 | 117.85M |
| June 30, 2020 | 43.24M |
| March 31, 2020 | 24.72M |
| December 31, 2019 | 37.91M |
| September 30, 2019 | 22.57M |
| June 30, 2019 | 19.50M |
| March 31, 2019 | -1.097M |
| December 31, 2018 | 83.30M |
| September 30, 2018 | 167.30M |
| June 30, 2018 | 47.17M |
| March 31, 2018 | 28.23M |
| December 31, 2017 | 28.51M |
| September 30, 2017 | 2.046M |
| June 30, 2017 | 45.60M |
| Date | Value |
|---|---|
| March 31, 2017 | -22.48M |
| December 31, 2016 | 45.13M |
| September 30, 2016 | -7.124M |
| June 30, 2016 | 91.18M |
| March 31, 2016 | 2.557M |
| December 31, 2015 | -2.11M |
| September 30, 2015 | -0.586M |
| June 30, 2015 | 0.06M |
| March 31, 2015 | -0.711M |
| December 31, 2014 | 45.45M |
| September 30, 2014 | -0.055M |
| June 30, 2014 | 26.70M |
| March 31, 2014 | 7.50M |
| December 31, 2013 | 32.21M |
| September 30, 2013 | 4.173M |
| June 30, 2013 | -0.049M |
| March 31, 2013 | 7.237M |
| December 31, 2012 | 0.0318M |
| September 30, 2012 | 0.00 |
| June 30, 2012 | 5.938M |
| March 31, 2012 | 0.00 |
| December 31, 2011 | 1.976M |
| September 30, 2011 | 0.00 |
| June 30, 2011 | 0.0079M |
| March 31, 2011 | -0.00 |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-11.58M
Minimum
Dec 2020
173.37M
Maximum
Mar 2022
52.78M
Average
40.06M
Median
Sep 2021
Cash from Financing (Quarterly) Benchmarks
| Scilex Holding Co | 8.306M |
| AIM ImmunoTech Inc | 0.147M |
| Perspective Therapeutics Inc | 0.352M |
| Protalix BioTherapeutics Inc | 0.00 |
| Armata Pharmaceuticals Inc | -0.043M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -55.66M |
| Cash from Investing (Quarterly) | -0.14M |
| Free Cash Flow | -243.21M |
| Free Cash Flow Per Share (Quarterly) | -0.1012 |
| Free Cash Flow to Equity (Quarterly) | -126.87M |
| Free Cash Flow to Firm (Quarterly) | -53.11M |